TG Therapeutics (TGTX) 10-Q2010 Q2 Quarterly report

Filed: 16 Aug 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absorb, accelerated, acid, advocate, age, alleviate, anemia, antacid, anxiety, arrangement, asymptomatic, atrophic, bifurcation, blood, bloodstream, body, brain, cancer, capability, cardiovascular, characterized, children, choice, chronic, circulating, circulatory, cognition, coincide, commensurate, compromised, confusion, Cooperative, cord, costly, CRADA, Crohn, cyanocobalamin, daily, damage, data, dementia, depression, diagnosed, diet, directly, disabling, disease, doctor, drinking, eating, effort, elderly, elevated, enable, enhancement, entirety, extinguishment, facile, facility, fatigue, fear, found, Framingham, freedom, frequency, frequent, frequently, gait, gastric, gastrointestinal, global, Glucophage, goal, healthy, Heart, hematological, high, higher, home, homocysteine, hydroxocobalamin, ideal, inability, incidence, inconvenience, inconvenient, injection, institute, insufficiency, internationally, intramuscular, intranasal, involuntary, left, lifelong, maintenance, methylmalonic, misdiagnosed, movement, nasal, NDA, necessitating, neurological, Neuronal, NIH, noncash, Noncurrent, nonsubstantive, nurse, nursing, nutritional, older, pain, painful, parenteral, Parkinson, patch, pathological, pathway, permanent, pharmacokinetic, physician, poorly, population, predominant, predominantly, prevalence, prevalent, Prilosec, problem, problematic, produce, profile, properly, proposed, range, rapidly, recommended, referred, regimen, remediation, replenish, restore, restoring, revenue, safe, satisfactorily, shaking, side, small, spinal, spray, standard, stomach, storage, strict, Stroke, sublingual, submission, substantive, substitute, surgical, therapeutic, therapy, tolerated, toxicology, tract, unapproved, underway, untested, untreated, upper, vegan, vendor, viable, visit, visiting, vitamin, voice, voluntary, weekly, wholly, writing

Removed: Altoderm, Altolyn, atopic, bowel, convenience, cromoglicate, inflammatory, licensed, lotion, royalty, skin, sodium, sublicense

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TGTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Manhattan Pharmaceuticals, Inc. does hereby certify that, to the best of his knowledge:

(a) the Quarterly Report on Form 10-Q of Manhattan Pharmaceuticals, Inc. for the quarter ended June 30, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Manhattan Pharmaceuticals, Inc.

Dated: August 16, 2010	/s/ Michael G. McGuinness
	Michael G. McGuinness
	Principal Executive and Financial Officer